MK-2866 and Primobolan Interaction

Avoid
Mechanism-based 64% confidence

MK-2866 and Primobolan have a potentially harmful interaction with 64% confidence. Both MK-2866 and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the gonads and liver and heart, so monitoring these systems is recommended.

Compound Profiles

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Half-life: ~24 hours Typical dose: 10-25 mg/day oral sarm, anabolic
androgen receptormtormyostatin androgeniccarcinogenic riskhepatotoxichpta suppressive
View full profile

Primobolan

Anabolic Steroid | Lean Mass & Low Side Effect Profile

Metenolone binds to the androgen receptor (AR) to promote nitrogen retention, protein synthesis, and anti-catabolic effects in skeletal muscle tissue. As a DHT derivative, it cannot be aromatized by the aromatase enzyme, meaning it produces no estrogenic metabolites and does not contribute to water retention, gynecomastia, or estrogen-mediated fat gain.

Half-life: ~10 days (enanthate) Typical dose: 400-800 mg/week (injectable) or 50-100 mg/day (oral) anabolic
5 alpha reductaseandrogen receptoraromataseepo receptor androgenicblood pressure raisingcarcinogenic riskhepatotoxic
View full profile

Combined Organ Load

Gonads
elevated
Liver
elevated
Heart
moderate

Shared Safety Flags

2x 2 androgenic compounds (MK-2866, Primobolan). Additive androgenic load — increased risk of hair loss, acne, prostate effects.
2x 2 compounds share the carcinogenic-risk safety flag (MK-2866, Primobolan). Monitor accordingly.
2x 2 hepatotoxic compounds (MK-2866, Primobolan). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.
2x 2 HPTA-suppressive compounds (MK-2866, Primobolan). Deep hormonal shutdown expected — plan extended PCT.
2x 2 compounds disrupt lipids (MK-2866, Primobolan). Get lipid panel mid-cycle — consider adding lipid support.

Frequently Asked Questions

Can I take MK-2866 with Primobolan?

Combining MK-2866 with Primobolan is not recommended. Both MK-2866 and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is MK-2866 and Primobolan safe together?

This combination carries significant risk. Both MK-2866 and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between MK-2866 and Primobolan?

Both MK-2866 and Primobolan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time MK-2866 and Primobolan?

MK-2866 has a half-life of ~24 hours and Primobolan has a half-life of ~10 days (enanthate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: MK-2866 vs Primobolan

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.